Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8575196

    Oligomer-opioid agonist conjugates

    Nektar Therapeutics · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8575359

    Acid-sensitive linkers for drug delivery

    The Regents of the University of California · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8574853

    Monoclonal antibodies that neutralize anthrax toxins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8575319

    Cleavable vaccine compositions and uses thereof and methods of making and using the same

    The Regents of the University of California · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8574545

    Labeled iodinated tropane formulation

    Alseres Pharmaceuticals, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8575119

    2′-chloroacetylenyl substituted nucleoside derivatives

    Enanta Pharmaceuticals, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8575185

    Compositions, synthesis, and methods of utilizing quinazolinedione derivatives

    REVIVA PHARMACEUTICALS, INC. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8575312

    Compositions and methods of use for MGD-CSF in disease treatment

    Five Prime Therapeutics, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8574468

    Benzo-fused heterocyclic chromophores for nonlinear optical devices

    United States of America as represented by the Secretary of the Air Force · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8574467

    Benzo-fused heterocyclic chromophores for nonlinear optical devices

    United States of America as represented by the Secretary of the Air Force · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8575327

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8575102

    Conjugates having a releasable linkage

    Nektar Therapeutics · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8575209

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8575208

    Inhibitors of serine proteases

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8575375

    Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8575192

    Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

    Theravance, Inc. · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8575123

    Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

    Tekmira Pharmaceuticals Corporation · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8574653

    Intermittent flow extrusion process and food product

    Del Monte Corporation · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8575154

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8575121

    Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8574618

    Perforated bioabsorbable oil film and methods for making the same

    ATRIUM MEDICAL CORPORATION · Granted Tue Nov 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. AU 2012249536

    Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

    CELGENE CORP [CH] · Granted Thu Nov 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8580921

    Protein nanorings

    Regents of the University of Minnesota · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8580927

    Engineered antibody constant domain molecules

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8580819

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8580252

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    HALOZYME, INC. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8580919

    Polymer conjugates of GLP-1

    Nektar Therapeutics · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8580231

    Compositions and methods comprising magnetic resonance contrast agents

    Northwestern University · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8580249

    Cell therapy for the treatment of lysosomal storage disorders

    Regents of the University of Minnesota · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8580245

    Compositions and methods for treating and preventing cardiomyopathy and heart disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8580293

    Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

    TEVA WOMEN'S HEALTH, INC. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8580290

    Heparosan-based biomaterials and coatings and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8580773

    Small-molecule inhibitors of the androgen receptor

    The Regents of the University of California · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8580738

    Methods for treatment of reperfusion injury and other cardiac conditions

    The Board of Regents of the University of Texas System · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8580768

    Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8580802

    Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8580811

    Androgen receptor modulator methods

    Ligand Pharmaceuticals Incorporated · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8580822

    Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

    REVIVA PHARMACEUTICALS, INC. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8580844

    Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities

    Georgia Regents Research Institute, Inc. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8580852

    2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides

    The Regents of the University of California · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8580845

    Functionalized expanded porphyrins

    The Board of Regents of the University of Texas System · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8580923

    Self-assembling peptide amphiphiles and related methods for growth factor delivery

    Northwestern University · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8580944

    Suppressors of CpG oligonucleotides and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8580936

    Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

    Five Prime Therapeutics, Inc. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8580748

    Peptides for the treatment of hearing

    Compass Therapeutics LLC · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8580735

    Local complement inhibition for treatment of complement-mediated disorders

    Apellis Pharmaceuticals, Inc. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8580263

    Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof

    The Regents of the University of California · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. EP 2662386

    Antikörper, die an PLAC1 binden und die Wechselwirkung zwischen PLAC1 und FGF7 inhibieren

    BIONTECH AG [DE] · Granted Wed Nov 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Nov 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.